Corium International Inc (NASDAQ:CORI) has been given a consensus rating of “Buy” by the nine ratings firms that are presently covering the company, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $13.00.
A number of brokerages recently issued reports on CORI. Needham & Company LLC cut their price objective on Corium International from $16.00 to $14.00 and set a “buy” rating for the company in a research note on Tuesday, December 26th. Cantor Fitzgerald restated a “buy” rating and issued a $14.00 target price on shares of Corium International in a research report on Friday, December 22nd. HC Wainwright set a $15.00 price objective on Corium International and gave the company a “buy” rating in a report on Friday, November 17th. Jefferies Group set a $10.00 price objective on Corium International and gave the company a “buy” rating in a report on Sunday, October 29th. Finally, Zacks Investment Research upgraded Corium International from a “sell” rating to a “hold” rating in a report on Tuesday, November 28th.
In other news, major shareholder Perceptive Advisors Llc bought 50,350 shares of Corium International stock in a transaction dated Tuesday, January 16th. The stock was acquired at an average cost of $11.83 per share, with a total value of $595,640.50. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Life Sciences Maste Perceptive bought 510,000 shares of Corium International stock in a transaction dated Thursday, January 18th. The stock was purchased at an average cost of $12.54 per share, with a total value of $6,395,400.00. The disclosure for this purchase can be found here. Corporate insiders own 30.80% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the business. MetLife Investment Advisors LLC purchased a new stake in Corium International during the 4th quarter valued at approximately $123,000. New York State Common Retirement Fund bought a new position in Corium International during the second quarter valued at approximately $158,000. California State Teachers Retirement System bought a new position in Corium International during the second quarter valued at approximately $263,000. Teachers Advisors LLC bought a new position in Corium International during the second quarter valued at approximately $272,000. Finally, California Public Employees Retirement System bought a new position in Corium International during the fourth quarter valued at approximately $310,000. 87.29% of the stock is owned by hedge funds and other institutional investors.
Corium International (NASDAQ:CORI) traded up $0.25 during midday trading on Tuesday, hitting $13.24. 145,617 shares of the stock traded hands, compared to its average volume of 147,884. Corium International has a 12-month low of $3.44 and a 12-month high of $13.93. The company has a debt-to-equity ratio of 5.91, a current ratio of 1.40 and a quick ratio of 1.34.
Corium International (NASDAQ:CORI) last posted its earnings results on Thursday, February 8th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.43) by $0.06. Corium International had a negative net margin of 148.07% and a negative return on equity of 403.15%. The firm had revenue of $9.32 million during the quarter, compared to analyst estimates of $7.48 million. analysts forecast that Corium International will post -1.43 earnings per share for the current fiscal year.
Corium International Company Profile
Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.
Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.